RxDoctor Payments Data

Anna Kinney

Physician Assistant · Nashville, TNNPI 1578164018

Payments from drug & device makers

$3,867in general payments, 2019–2025

Across 129 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Johnson & Johnson$534
  • Sumitomo Pharma America, Inc.$440
  • Pfizer$416
  • Tolmar, Inc.$236
  • Antares Pharma, Inc.$156
  • plus $860 from 21 others

What the payments were for

  • Travel & lodging$76320%
  • Food & beverage$3,03779%
  • Education$682%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,867 in reported general payments places this provider in the 85th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$194,918
Medicare patients
496
Services billed
11,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron58$48,441
GemtesaVibegron51$36,218
FirmagonDegarelix Acetate14$8,182
Potassium Citrate ErPotassium Citrate32$3,414
Testosterone Cypionate63$2,450
NitrofurantoinNitrofurantoin Macrocrystal15$1,614
Tamsulosin Hcl104$1,293
Alfuzosin Hcl ErAlfuzosin Hcl52$1,195
Testosterone11$1,120
Cefdinir86$845
Desmopressin Acetate13$617
Allopurinol14$283
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$255
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$124
Anastrozole36$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$21$48,44158 claims
Sumitomo Pharma America, Inc.Gemtesa$440$36,21851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →